Get the latest tech news

Cancer Therapy Shows Zero Toxicity at 100× Dose—Sona Nanotech's Gold Nanorod Technology Clears Major FDA Hurdle

Halifax, Nova Scotia--(Newsfile Corp. - May 27, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is...

Donald Hodges, PhD, DSP, DABT, Head of Integrated Toxicology at CBSET, Inc., commented, " This study indicates Sona's gold nanorods were well tolerated, with no signs of acute or systemic toxicity at 100 times the proposed clinical dosage level. The study evaluated the safety, tolerability, and tissue distribution of Sona's nanoparticles in three cohorts of twenty rats each at different dosage levels following intravenous administration. Sona's uniquely biocompatible gold nanorods demonstrated"a favorable safety profile, with tissue distribution consistent with nanoparticle pharmacokinetics and no evidence of acute or systemic toxicity."

Get the Android app